Table 1.
List of miRNA SNPs evaluated in solid cancer epidemiologic studies
| Polymorphism | SNP ID | miRNA/gene | Allele | Description | Size of cohort cases/controls | Population | Risk (95% CI) | Reference |
|---|---|---|---|---|---|---|---|---|
| Breast cancer | ||||||||
| Pre-miRNA | rs11614913 | miR-196-a2 | T/C | Increased risk | 1009/1093 | Chinese | 1.23 (1.02–1.48) | 45 |
| C/T | Decreased risk | 475/502 | United States | 0.44 (0.28–0.70) | 46 | |||
| Lack of association | 1894/2760 | Italian, German | NS | 47 | ||||
| rs3746444 | miR-499 | A/G | Lack of association | 1894/2760 | Italian, German | NS | 47 | |
| Increased risk | 1009/1093 | Chinese | 1.25 (1.02–1.51) | 45 | ||||
| rs2910164 | miR-146a | G/C | Earlier age of onset | 42 case-only | United States | Not given | 48 | |
| Lack of association | 1894/2760 | Italian, German | NS | 47 | ||||
| Lack of association | 1894/2760 | Italian, German | NS | 47 | ||||
| rs895819 | miR-27a | A/G | Decreased risk | 1217/1422 | German | 0.88 (0.78–0.99) | 49 | |
| C/T | Decreased risk | 363BRCA1/125 BRCA2 | Jewish | 1.96 (1.16–3.33) for TC versus TT | 50 | |||
| rs6505162 | miR-423 | A/C | Increased risk | 363BRCA1/125 BRCA2 | Jewish | 2.77 (1.11–6.9) | 50 | |
| miRNA-binding site | rs743554 | ITGB4 (miR-34a) | G/A | Reduced survival | 749/1493 | Swedish | 2.11 (1.21–3.68) | 51 |
| rs2747648 | ESR1 (miR-453) | C/T | Increased risk | 1223/1495 | German | 0.60 (0.41–0.89) for C versus T allele | 52 | |
| rs16917496 | SET8 (miR-502) | T/C | Earlier age of onset | 1110/1097 | Chinese | 1.66 (1.06–2.61) for CC versus TT | 53 | |
| rs1434536 | BMPR1B (miR-125b) | C/T | Increased risk | 459+1145/1142 | US/ethnicity data not available | 1.94 (1.40–2.71) for TT versus CC | 54 | |
| Colorectal cancer | ||||||||
| miRNA biogenesis | frameshift mut. | Ago2 | Associated with MSI-H | 100 case-only | Korean | Not given | 55 | |
| frameshift mut. | TNRC6A | Associated with MSI-H | 100 case-only | Korean | Not given | 55 | ||
| Pre-miRNA | rs2289030 | miR-492 | C/G | Reduced survival | 426 case-only | Korean | 1.19 (0.73–1.93) | 56 |
| miRNA-binding site | rs17281995 | CD86 (5 miRNAs) | G/C | Increased risk | 697/624 | Central-European | 2.93 (1.29–6.67) | 57 |
| rs1051690 | INSR (miR-612) | G/A | Increased risk | 697/624 | Central- | 1.86 (0.99–3.50) | 57 | |
| rs61764370 | KRAS (let-7) | T/G | EGFR therapy response | 130 case-only | European United States | Not given | 58 | |
| Lung cancer (NSCLC) | ||||||||
| Pre-miRNA | rs11614913 | mir-196-a2 | T/C | Increased risk | 1058/1035 | Chinese | 1.25 (1.01–1.54) | 59 |
| Reduced survival | 663 case-only | Chinese | 1.29 (1.01–1.65) | 60 | ||||
| miRNA-binding site | rs61764370 | KRAS (let-7) | T/G | Increased risk | 2433 -pooled | Worldwide | 2.39 (1.1–4.6) | 61 |
| Lack of association | 461 case-only | United States | NS | 62 | ||||
| Prostate cancer | ||||||||
| Pre-miRNA | rs2910164 | miR-146a | G/C | Decreased risk | 251/280 | Chinese | 0.65 (0.43–0.99) | 63 |
| Renal cell carcinoma | ||||||||
| miRNA biogenesis | rs2740348 | GEMIN4 | G/C | Decreased risk | 276/278 | US Caucasians | 0.67 (0.47–0.96) | 64 |
| rs7813 | GEMIN4 | T/C | Decreased risk | 277/278 | US Caucasians | 0.68 (0.47–0.96) | 64 | |
| rs197412 | GEMIN3 | T/C | Increased risk | 277/278 | US Caucasians | 1.31 (0.93–1.85) | 64 | |
| rs11077 | XPO5 | A/C | Increased risk | 276/277 | US Caucasians | 1.55 (0.98–2.44) | 64 | |
| Cervical cancer | ||||||||
| Pri-miRNA | rs11134527 | miR-218 | A/G | Decreased risk | 703/713 | Chinese | 0.72 (0.52–0.99) | 66 |
| miRNA-binding site | rs2566 | LAMB3 | C/T | Increased risk | 703/713 | Chinese | 1.57 (1.25–1.96) | 66 |
| Ovarian cancer | ||||||||
| Pre-miRNA | rs2910164 | miR-146a | G/C | Earlier age of onset | 82 case-only | United States | Not given | 48 |
| rs6505162 | miR-423 | A/C | Increased risk | 363BRCA1/125BRCA2 | Jewish | 2.77 (1.11–6.9) | 50 | |
| rs2740351 | GEMIN4 | G/C | Decreased risk | 339/349 | United States | 0.71 (0.57–0.87) | 67 | |
| rs7813 | GEMIN4 | T/C | Decreased risk | 339/349 | United States | 0.71 (0.57–0.88) | 67 | |
| miRNA biogenesis | rs12194974 | LIN28B | G/A | Decreased risk | 1815/1900 | United States | 0.90 (0.82–0.98) | 68 |
| Gastric cancer | ||||||||
| Pre-miRNA | rs895819 | miR-27a | A/G | Increased risk | 340/304 | Chinese | 1.48 (1.06–2.05) | 69 |
| rs11614913 | miR-196-a2 | T/C | Increased risk | 213/213 | Chinese | 1.57 (1.03–2.39) | 70 | |
| Bladder cancer | ||||||||
| miRNA biogenesis | rs7813 | GEMIN4 | T/C | Decreased risk | 736/736 | United States | 0.78 (0.60–1.02) | 71 |
| rs197414 | GEMIN3 | A/C | Increased risk | 740/742 | United States | 2.50 (1.08–5.78) | 71 | |
| rs784567 | TRBP | C/T | Decreased risk | 737/729 | United States | 0.80 (0.62–1.02) | 71 | |
| Pri-miRNA | rs7372209 | miR-26a-1 | C/T | Decreased risk | 728/728 | United States | 0.68 (0.45–1.04) | 71 |
| rs531564 | miR-124–1 | C/G | Increased risk | 739/740 | United States | 2.44 (0.96–6.20) | 71 | |
| Pre-miRNA | rs2289030 | miR-492 | C/G | Increased risk | 739/734 | United States | 1.35 (0.98–1.87) | 71 |
| rs6505162 | miR-423 | A/C | Increased risk | 723/733 | United States | 1.25 (0.96–1.61) | 71 | |
| Oesophageal cancer | ||||||||
| miRNA biogenesis | rs11077 | XPO5 | A/C | Increased risk | 346/346 | United States | 1.58(1.03–2.45) | 72 |
| rs14035 | RAN | C/T | Increased risk | 346/346 | United States | 1.99(1.17–3.38) | 72 | |
| Pri-miRNA | rs7372209 | miR-26a-1 | C/T | Increased risk | 346/346 | United States | 1.35(1.04–1.76) | 72 |
| rs213210 | miR-219–1 | T/C | Increased risk | 346/346 | United States | 1.75(1.10–2.80) | 72 | |
| Pre-miRNA | rs11614913 | miR-196-a2 | T/C | Increased risk | 346/346 | United States | 1.73(1.16–2.56) | 72 |
| rs2910164 | miR-146a | G/C | Increased risk | 444/468 | Chinese | 2.39 (1.36–4.20) | 73 | |
| rs6505162 | miR-423 | A/C | Increased risk | 346/346 | United States | 0.64(0.51–0.80) | 72 | |
| Hepatocellular carcinoma | ||||||||
| Pre-miRNA | rs2910164 | miR-146a | G/C | Increased risk | 479/504 | Chinese | 2.02 (1.06–3.85) for GG versus CC | 74 |
| rs11614913 | miR-196-a2 | T/C | Increased risk | 560/391 | Chinese | 1.18 (0.73–1.93) for CC versus TT | 75 | |
| miRNA-binding site | rs3783553 | IL1A (miR-122, miR-378) | Del/Ins | Increased risk | 1477/1673 | Chinese | 0.62 (0.49–0.78) for ++ versus (+− and –) | 76 |
| Head and neck cancer | ||||||||
| Pre-miRNA | rs11614913 | miR-196-a2 | T/C | Increased risk | 1039 | United States | 7.4 (1.9–28.2) | 77 |
| Thyroid cancer | ||||||||
| Pre-miRNA | rs2910164 | miR-146a | G/C | Decreased risk | 206/274 | Finnish | 0.42 (0.24–0.73) for CC against GC_GG | 78 |
| Glioma | ||||||||
| Pre-miRNA | rs11614913 | miR-196-a2 | T/C | Decreased risk | 670/680 | Chinese | 0.74 (0.56–0.98) | 80 |